Therapeutic Conundrum: Infective Endocarditis due to Extensively Drug-resistant Pseudomonas aeruginosa Treated with Ceftazidime/Avibactam Monotherapy: A Case Report
Citation Information :
Ajapuje P, Patwardhan S, Dawra R, Sathe S, Kanase D, Javdekar N, Juvekar N, Melinkeri A, Prayag A. Therapeutic Conundrum: Infective Endocarditis due to Extensively Drug-resistant Pseudomonas aeruginosa Treated with Ceftazidime/Avibactam Monotherapy: A Case Report. 2023; 2 (4):88-90.
Infective endocarditis (IE) is a significant cause of mortality and morbidity, especially in patients with underlying acquired structural heart disease in developing countries. IE caused by non-Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella (HACEK) gram-negative bacteria (GNB) accounts for approximately 2% of all cases and is characterized by high mortality. Pseudomonas aeruginosa (P. aeruginosa) IE accounts for <0.4% of all endocarditis cases. Gram-negative endocarditis is further compounded by the problem of antimicrobial resistance. We report a very rare case of carbapenem-resistant P. aeruginosa IE (CRIE) from India to highlight the difficulties of managing such cases with the challenges of antimicrobial resistance in our settings.
Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis-prospective cohort study. Arch Intern Med 2009;169(5):463–473. DOI: 10.1001/archinternmed.2008.603
Morpeth S, Murdoch D, Cabell CH, et al. Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med 2007;147(12):829–835. DOI: 10.7326/0003-4819-147-12-200712180-00002
Falcone M, Tiseo G, Durante-Mangoni E, et al. Risk factors and outcomes of endocarditis due to non-HACEK gram-negative bacilli: data from the prospective multicenter Italian endocarditis study cohort. Antimicrob Agents Chemother 2018;62(4):e02208–e02217. DOI: 10.1128/AAC.02208-17
Viola GM, Awan LL, Ostrosky-Zeichner L, et al. Infections of cardiac implantable electronic devices: a retrospective multicenter observational study. Medicine (Baltimore) 2012;91(3):123–130. DOI: 10.1097/MD.0b013e31825592a7
Hagiya H, Tanaka T, Takimoto K, et al. Non-nosocomial healthcare-associated left-sided Pseudomonas aeruginosa endocarditis: a case report and literature review. BMC Infect Dis 2016;16(1):431. DOI: 10.1186/s12879-016-1757-y
Dawson NL, Brumble LM, Pritt BS, et al. Left-sided Pseudomonas aeruginosa endocarditis in patients without injection drug use. Medicine (Baltimore) 2011;90(4):250–255. DOI: 10.1097/MD.0b013e3182252133
Wieland M, Lederman MM, Kline-King C, et al. Left-sided endocarditis due to Pseudomonas aeruginosa. A report of 10 cases and review of the literature. Medicine (Baltimore) 1986;65(3):180–189. DOI: 10.1097/00005792-198605000-00006
Ben-Ami R, Giladi M, Carmeli Y, et al. Hospital-acquired infective endocarditis: should the definition be broadened? Clin Infect Dis 2004;38(6):843–850. DOI: 10.1086/381971
Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Eur Heart J 2015;36(44):3075–3128. DOI: 10.1093/eurheartj/ehv319
Lima O, Sousa A, Filgueira A, et al. Successful ceftazidime-avibactam therapy in a patient with multidrug-resistant pseudomonas aeruginosa infective endocarditis. Infection 2022;50(4):1039–1041. DOI: 10.1007/s15010-022-01834-7
Soman R, Gupta N, Chaudhari P, et al. Implications for diagnosis and treatment of infective endocarditis: eight-year experience of an infectious disease team in a private tertiary care centre. J Assoc Physicians India 2018;66(4):22–25.